Prostate Cancer Therapy - Active Hexose-Correlated Compound (AHCC) - Part 2
While the first part of this article introduces the AHCC prostate cancer treatment therapy, this second part looks into how it's being used today in the treatment of the condition.
Today, AHCC has found use even with chemotherapy drugs because it has demonstrated such potential in antitumor activity and immune modulator activity that it is now relied upon to do precisely that when administered orally.
Although there is no current information regarding its metabolism and the potential for drug interactions of AHCC in combination with chemotherapy employed now for late state or metastatic prostate cancers, there is a good degree of confidence that it will not fail to at least slow disease progression and even cause cancerous cell apoptosis.
With a simple dosage of no more than three grams of the compound a day, the Active Hexose Correlated Compound have been said to kill cancer cells in the body with no major side effects whatsoever, at least none that have been found as recently as when the product was announced in medical journals as of April 2009.
But you know how it is with scientists and how they like to play safe.
For them, more research is needed on AHCC before any firm recommendations on effectiveness, dosage, frequency and length of use are made.
Certainly they still need a better understanding of its interactions with radiotherapy and chemo, as well as the best conditions for which it can be useful, especially since they have only carried out few human tests with it.
We can hardly wait for the results so that we can know if all this AHCC combination therapy for prostate cancer is the breakthrough that humanity as been waiting for, not only in prostate type of cancer treatment, but for all forms of cancer everywhere.
Today, AHCC has found use even with chemotherapy drugs because it has demonstrated such potential in antitumor activity and immune modulator activity that it is now relied upon to do precisely that when administered orally.
Although there is no current information regarding its metabolism and the potential for drug interactions of AHCC in combination with chemotherapy employed now for late state or metastatic prostate cancers, there is a good degree of confidence that it will not fail to at least slow disease progression and even cause cancerous cell apoptosis.
With a simple dosage of no more than three grams of the compound a day, the Active Hexose Correlated Compound have been said to kill cancer cells in the body with no major side effects whatsoever, at least none that have been found as recently as when the product was announced in medical journals as of April 2009.
But you know how it is with scientists and how they like to play safe.
For them, more research is needed on AHCC before any firm recommendations on effectiveness, dosage, frequency and length of use are made.
Certainly they still need a better understanding of its interactions with radiotherapy and chemo, as well as the best conditions for which it can be useful, especially since they have only carried out few human tests with it.
We can hardly wait for the results so that we can know if all this AHCC combination therapy for prostate cancer is the breakthrough that humanity as been waiting for, not only in prostate type of cancer treatment, but for all forms of cancer everywhere.